Related Experiment Videos
[Hepatic artery embolization therapy for advanced hepatoma].
Nihon Geka Gakkai Zasshi
|September 1, 1983
Summary
Hepatic artery embolization shows promising survival rates for hepatoma patients, outperforming intrahepatic arterial chemotherapy. Advanced liver cirrhosis does not appear to negatively impact outcomes for this treatment.
Area of Science:
- Hepatobiliary Surgery
- Interventional Radiology
- Oncology
Context:
- Hepatoma (liver cancer) presents significant treatment challenges.
- Hepatic artery embolization (HAE) is an established palliative treatment for unresectable hepatoma.
- Comparing HAE efficacy against other treatments like intrahepatic arterial chemotherapy is crucial.
Purpose:
- To evaluate the survival outcomes of hepatic artery embolization for advanced hepatoma.
- To investigate the histological impact of HAE on liver tissue.
- To assess the influence of liver cirrhosis on HAE treatment effectiveness.
Summary:
- A study of 244 hepatoma cases treated with HAE revealed 1, 2, and 3-year survival rates of 45%, 27%, and 12%, respectively.
- HAE demonstrated a significantly higher 1-year survival rate (45%) compared to intrahepatic arterial chemotherapy (7%).
- Histological examination showed necrosis in cases with portal vein occlusion but not in cirrhotic livers with patent portal veins.
Impact:
- HAE offers a survival benefit for advanced hepatoma patients compared to chemotherapy.
- Liver cirrhosis may not be a contraindication for HAE and could even be associated with long-term survival.
- Findings support HAE as a viable therapeutic option for advanced hepatoma, even in the presence of severe liver cirrhosis.